CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
|Articles|November 1, 2001
Supplements and Featured Publications
- New Directions in the Treatment and Prevention of Deep Vein Thrombosis
- Volume 7
- Issue 17 Suppl
Participating Faculty
Advertisement
Articles in this issue
almost 25 years ago
Introductionalmost 25 years ago
Treatment of Deep Vein Thrombosis Using Low-Molecular-Weight Heparinsalmost 25 years ago
Prophylaxis Strategies for Patients with Acute Venous Thromboembolismalmost 25 years ago
Interviewalmost 25 years ago
Continuing Medical Education Quizalmost 25 years ago
Literature ReviewAdvertisement
Related to this article
At inSPire2026, experts highlighted gaps in specialty therapy payment, 340B data, clinical trials, and AI-driven care.
The approval is based on findings from the phase 3 SCOUT-HCM trial.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote monitoring policies.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
A higher ratio of red blood cell distribution width to albumin was tied to greater all-cause, cardiovascular, and cancer mortality in adults with CKD.
A meta-analysis of 22 studies found steatotic liver disease in about three-quarters of patients with sleep-disordered breathing.
Advertisement
Advertisement
Trending on AJMC
1
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
2
CMS Projects 16.5% Drop in 2027 Medicare Advantage Premiums
3
FDA Accepts Inhaled Treprostinil sNDA for IPF: 4 FAQs for Payers
4
Proposed Medicare Rate Cuts Draw AASM Opposition Ahead of Final Rule
5